- Home
- / ReViral
ReViral
Total Funding
$121 M
ReViral Summary
Company Summary
- Overview
- ReViral is a biotechnology company developing drugs to treat RSV infections. It develops a small molecule inhibitor of RSV fusion RV521 to help children, the elderly and the immune-compromised.
- Type
- Private
- Status
- Active
- Founded
- 2011
- HQ
- Stevenage, GB | view all locations
- Website
- https://www.reviral.co.uk/
- Cybersecurity rating
Table of Contents
Key People
Ian Armstrong, Head of Formulation Development
Eddy Littler, Chief Operating Officer
Raphaël Wisniewski, Director
LocationsView all
2 locations detected
Stevenage, England HQ
United Kingdom
Gunnels Wood Rd
Durham, NC
United States
2530 Meridian Parkway 2nd & 3rd Floors